Learn more

BAKER JR JAMES R

Overview
  • Total Patents
    32
  • GoodIP Patent Rank
    231,022
About

BAKER JR JAMES R has a total of 32 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are YISHENG BIOPHARMA SINGAPORE PTE LTD, ALLERGY THERAPEUTICS UK LTD and ADVANCED BIOADJUVANTS LLC.

Patent filings in countries

World map showing BAKER JR JAMES Rs patent filings in countries

Patent filings per year

Chart showing BAKER JR JAMES Rs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Baker Jr James R 32
#2 Hamouda Tarek 9
#3 Makidon Paul E 7
#4 Myc Andrzej 7
#5 Thomas Thommey P 6
#6 Cheng Xue-Min 5
#7 Bielinska Anna U 5
#8 Huang Baohua Mark 4
#9 Ciotti Susan M 4
#10 Shih Amy 4

Latest patents

Publication Filing date Title
WO2016057921A1 Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
US2014093537A1 Immunogenic compositions comprising nanoemulsion and methods of administering the same
US2013273113A1 Immunogenic apoptosis inducing compositions and methods of use thereof
US2012258137A1 Immunogenic compositions comprising nanoemulsion and hepatitis b virus immunogen and methods of using the same
US2012064136A1 Anti-aging and wrinkle treatment methods using nanoemulsion compositions
WO2012003361A2 Nanoemulsion vaccines
US2012171227A1 Pro-drug complexes and related methods of use
US2012128719A1 Streptococcus vaccine compositions and methods of using the same
WO2010075423A2 Dendrimer based modular platforms
WO2010036945A2 Nanoemulsion therapeutic compositions and methods of using the same
WO2009151687A2 Dendrimer conjugates
US2009143477A1 Antimicrobial nanoemulsion compositions and methods
US2015266933A1 Compositions and methods for Bacillus anthracis vaccination
US2008026988A1 Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen